文献速递胸部肿瘤

Pegilodecakin联合检查点抑制剂治疗转移性NSCLC的随机II期研究

Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2).
PubMed 文献 · J Thorac Oncol · 2020-11-06

CYPRESS 1和CYPRESS 2两项随机II期研究分别评估Pegilodecakin联合帕博利珠单抗(一线)或纳武利尤单抗(二线)对比单药CPI在转移性NSCLC中的疗效与安全性。结果显示联合治疗未改善ORR、PFS或OS,且≥3级治疗相关不良事件和因不良事件停药率明显增加。

要点

  • 联合Pegilodecakin未改善ORR、PFS或OS。
  • 联合组因不良事件停药率翻倍,≥3级贫血和血小板减少增加。
  • 外周血见免疫激活信号,但未转化为临床获益。

核心结论

  • 尽管在外周血中观察到生物学效应,但在晚期NSCLC一线或二线治疗中,Pegilodecakin联合CPI未改善ORR、PFS或OS。
  • Pegilodecakin联合CPI总体毒性高于CPI单药,导致因不良事件停药率翻倍。

研究设计与样本

  • CYPRESS 1(N=101)为一线治疗,CYPRESS 2(N=52)为二线治疗,入组ECOG PS 0-1、无已知EGFR/ALK突变的转移性NSCLC患者。
  • 两项研究均按1:1随机,对照组分别接受帕博利珠单抗(CYPRESS 1)或纳武利尤单抗(CYPRESS 2),试验组接受Pegilodecakin联合CPI。
  • CYPRESS 1要求PD-L1 TPS≥50%,CYPRESS 2要求PD-L1 TPS 0%-49%。
  • 主要终点为研究者评估的ORR,次要终点包括PFS、OS和安全性,探索性终点包括免疫激活生物标志物。

主要发现

  • CYPRESS 1中位随访10.0个月,Pegilodecakin+帕博利珠单抗对比帕博利珠单抗:研究者评估ORR 47% vs 44%(OR=1.1,95%CI 0.5-2.5),中位PFS 6.3 vs 6.1个月(HR=0.937,95%CI 0.54-1.625),中位OS 16.3个月 vs 未达到(HR=1.507,95%CI 0.708-3.209)。
  • CYPRESS 1中BICR评估结果与研究者评估一致。
  • CYPRESS 2中位随访11.6个月,Pegilodecakin+纳武利尤单抗对比纳武利尤单抗:研究者评估ORR 15% vs 12%(OR=1.2,95%CI 0.3-5.9),中位PFS 1.9 vs 1.9个月(HR=1.006,95%CI 0.519-1.951),中位OS 6.7 vs 10.7个月(HR=1.871,95%CI 0.772-4.532)。
  • 生物标志物数据提示含Pegilodecakin组存在IL-10R通路免疫刺激信号激活。

关键数值与推荐

  • CYPRESS 1中因不良事件停药率:试验组32% vs 对照组15%;≥3级治疗相关不良事件:62% vs 19%,包括贫血(20% vs 0%)和血小板减少(12% vs 2%)。
  • CYPRESS 2中≥3级治疗相关不良事件:70.4% vs 16.7%,包括贫血(40.7% vs 0%)、乏力(18% vs 0%)和血小板减少(14.8% vs 0%)。

临床怎么用

  • 不推荐在转移性NSCLC的一线或二线治疗中常规联合Pegilodecakin与CPI。
  • 临床决策时应权衡联合治疗增加的毒性风险,尤其是贫血和血小板减少。

局限性

  • 两项研究样本量较小(CYPRESS 1 N=101,CYPRESS 2 N=52),统计效能有限。
  • 随访时间较短(中位10.0和11.6个月),OS数据尚不成熟。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Checkpoint inhibitors (CPIs) have been approved to treat metastatic NSCLC. Pegilodecakin + CPI suggested promising efficacy in phase 1 IVY, providing rationale for randomized phase 2 trials CYPRESS 1 and CYPRESS 2. METHODS: CYPRESS 1 (N = 101) and CYPRESS 2 (N = 52) included Eastern Cooperative Oncology Group performance status of 0 to 1 and first-line/second-line metastatic NSCLC, respectively, without known EGFR/ALK mutations. Patients were randomized 1:1; control arms received pembrolizumab (CYPRESS 1) or nivolumab (CYPRESS 2); experimental arms received pegilodecakin + CPI. Patients had programmed death-ligand 1 tumor proportion score of greater than or equal to 50% (CYPRESS 1) or 0% to 49% (CYPRESS 2). Primary end point was objective response rate (ORR) per investigator. Secondary end points included progression-free survival (PFS), overall survival (OS), and safety. Exploratory end points included immune activation biomarkers. RESULTS: Median follow-up for CYPRESS 1 and CYPRESS 2 was 10.0 and 11.6 months, respectively. Results for pegilodecakin + pembrolizumab versus pembrolizumab were as follows: ORR per investigator 47% versus 44% (OR = 1.1, 95% confidence interval [CI]: 0.5-2.5); median PFS 6.3 versus 6.1 months (hazard ratio [HR] = 0.937, 95% CI: 0.54-1.625); and median OS 16.3 months versus not reached (HR = 1.507, 95% CI: 0.708-3.209). Results per blinded independent central review were consistent. Treatment discontinuation rate owing to adverse events (AEs) doubled in the experimental arm (32% versus 15%). AEs with grade greater than or equal to 3 treatment-related AEs (62% versus 19%) included anemia (20% versus 0%) and thrombocytopenia (12% versus 2%). Results for pegilodecakin + nivolumab versus nivolumab were as follows: ORR per investigator 15% versus 12% (OR = 1.2, 95% CI: 0.3-5.9); median PFS 1.9 versus 1.9 months (HR = 1.006, 95% CI: 0.519-1.951); and median OS 6.7 versus 10.7 months (HR = 1.871, 95% CI: 0.772-4.532). AEs with grade greater than or equal to 3 treatment-related AEs (70.4% versus 16.7%) included anemia (40.7% versus 0%), fatigue (18% versus 0%), and thrombocytopenia (14.8% versus 0%). Biomarker data suggested activation of immunostimulatory signals of interleukin-10R pathway in pegilodecakin-containing arms. CONCLUSIONS: Despite evidence of biological effect in peripheral blood, adding pegilodecakin to CPI did not improve ORR, PFS, or OS, in first-line/second-line NSCLC. Pegilodecakin + CPI has been found to have overall higher toxicity compared with CPI alone, leading to doubling of treatment discontinuation rate owing to AEs.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Spigel D, Jotte R, Nemunaitis J, et al. Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2). J Thorac Oncol. 2020. PMID: 33166722. doi:10.1016/j.jtho.2020.10.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。